OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company focused on antibody discovery technologies, offering proprietary transgenic animal platforms that pharmaceutical partners use to generate fully human therapeutic antibody sequences. The company became publicly traded through a SPAC merger with Avista Public Acquisition Corp. II, sponsored by Avista Capital Partners, which completed in October 2022 following the SPAC's 2021 IPO. OmniAb filed this Form 8-K with the SEC on May 7, 2026, reflecting its continued reporting obligations as an operating public company in the life sciences and biopharmaceutical sector. For comprehensive filing history, deal timelines, and SPAC analytics on OmniAb and thousands of other transactions, sign up for SpacDesk.